miRNA Expression in Lower and Upper Urothelial Carcinoma and the Potential Clinical Application
Shuanzeng Wei, Yuan Yao, Prabodh K Gupta, Zhanyong Bing. Hospital of the University of Pennsylvania, Philadelphia, PA
Background: Diagnosis and follow-up of patients with urinary tract tumors currently are based on urine cytology, radiographic imaging, and ureteroscopy. Although urine cytology has a high specificity, it is not sensitive. Ureteroscopy is a reliable approach for identification of macroscopic disease. But the disadvantage of ureteroscopy is also evident, such as, discomfort, urinary tract infection, as well as failing to detect microscopic disease. MicroRNAs (miRNA) are short noncoding RNA molecules that posttranscriptionally modulate protein expression. There are distinct miRNA alterations characterizing urinary bladder urothelial carcinoma. In this study, we investigate the possibility of using miRNAs as a non-invasive markers in the screening or follow-up of urothelial cell carcinoma (UCC) from upper urinary tract and bladder.
Design: Total RNA was extracted from 87 bladder or renal washing fluid (22 high grade UCC, 13 low grade UCC, 25 normal control, 27 cases of positive history of UCC but negative at time of test (HIS)). All the diagnoses were confirmed by cytology and/or surgical pathology. Expression of miRNA markers miR-96, miR-182, miR-183, miR-200c, miR-21, miR-141, miR-30b were determined using quantitative real time PCR.
Results: Quantitative real time PCR showed miRNA is stable in the urinary tract washing fluid. miRNA-96, 182, 183, 141, 30b, 21 and 200c are overexpressed in high grade UCC compared to low grade UCC, normal control and HIS. There is no significant difference between the low grade, normal and HIS. In addition, UCC from upper GU tract and bladder cancers demonstrate similar changes of these target miRNAs.
Conclusions: Our study shows miRNAs are stable in the bladder or renal washing, and the target miRNAs (miRNA-96, 182, 183, 141, 30b, 21 and 200c) are overexpressed in high grade tumors. Real-time PCR of a panel of miRNA could be used as a screening test as well as a followup test for recurrence of UCC patient.
Category: Genitourinary (including renal tumors)
Wednesday, March 6, 2013 9:30 AM
Poster Session V # 156, Wednesday Morning